Page 64 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

period, Nivolumab treatment was discontinued in 17 patients (77.3%) because of

disease progression (n = 8, 36.4%), economic problems (n = 7, 31.8%), and adverse

event (n = 2, 9.1%). The median duration of nivolumab treatment was 4.42 months

(range, 0.59‐24.87 months) with a median cycle of six (range, 2‐34). Complete

response (CR) was noted in 3 patients (13.6%) and partial response (PR) in 6 patients

(27.3%). 8 patients (36.4%) died and 6 (27.3%) experienced disease progression

based on RECIST v1.1. The median overall survival (OS) was not reached till 25.2

months (Figure 1). The median of progression free survival (PFS) was 8.1 months

(Figure 2). The OS, PFS, CR, and PR were comparable between Nivolumab

monotherapy group and concurrent Nivolumab plus radiation therapy group (Table 2).

Conclusion: Nivolumab alone or combined radiation therapy is effective for

unresectable HCC patients. Patients who received concurrent Nivolumab plus

radiation therapy had comparable OS, PRS, CR, and PR compared with those

receiving Nivolumab alone. However, large-scale study is needed for further

investigation.